Loading...
FBRX logo

Forte Biosciences, Inc.NasdaqCM:FBRX Rapporto sulle azioni

Cap. di mercato US$1.9b
Prezzo delle azioni
n/a
1Y589.9%
7D0.1%
1D0.03%
Valore del portafoglio
​
Vista

Forte Biosciences, Inc.

Report azionario NasdaqCM:FBRX

Capitalizzazione di mercato: US$1.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Forte Biosciences (FBRX) Panoramica del titolo

Forte Biosciences, Inc. opera come azienda biofarmaceutica in fase clinica negli Stati Uniti. Maggiori dettagli

FBRX analisi fondamentale
Punteggio fiocco di neve
Valutazione1/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria6/6
Dividendi0/6

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Prezzo delle azioni altamente volatile negli ultimi 3 mesi rispetto al mercato US

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Si prevede che gli utili diminuiranno in media di 37.6% all'anno per i prossimi 3 anni

+ 1 più rischio

FBRX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW439,757 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
439,757 investors already sharing narratives
View all narratives

Concorrenti di Forte Biosciences, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Forte Biosciences
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$76.99
Massimo di 52 settimaneUS$77.20
Minimo di 52 settimaneUS$10.11
Beta2.64
Variazione di 1 mese0.64%
Variazione a 3 mesi270.68%
Variazione di 1 anno589.87%
Variazione a 3 anni274.60%
Variazione a 5 anni-89.71%
Variazione dall'IPO-81.67%

Notizie e aggiornamenti recenti

Recent updates

Articolo di analisi • Nov 11

We're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Forte Biosciences...
Articolo di analisi • Apr 19

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Jul 17

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Mar 14

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 24

Large Forte Biosciences shareholder scolds company board of directors

Funicular Funds, which owns 8% of the outstanding shares of Forte Biosciences (NASDAQ:FBRX), excoriated the company's board of directors in a letter over a recent capital raise. In an SEC filing, Funicular said the letter addressed the "Board’s failure to address the legitimate concerns previously raised by stockholders and its decision to embark on a value-destructive, scorched-earth path with a dilutive and unnecessary capital raise, without so much as an explanation for its actions." Funicular is asking to establish a committee of independent directors to investigate shareholder concerns. In July, a pair of large shareholders demanded changes at Forte (FBRX), including a suggestion that the company liquidate.
Articolo di analisi • Aug 17

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 16

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

FB-401, the lead asset failed in clinical trials. The company has one very early-stage asset they intend to move forward in the clinic, FB-102. Investors are likely to encounter dilution, a high degree of clinical risk and there is insufficient evidence to assess whether FB-401 has any advantages over other therapeutics. Summary Creativity is not my strength so I am reusing the title from an article that I wrote a few months back about Vyne Therapeutics, another dermatology company. The shares of Vyne have fallen 60% since then. The story is at Forte is essentially the same and all too common in biotech. Vyne and Forte both experienced setbacks, institutional investors sold and long term investors have fared poorly. Most importantly, for both companies, there is a suboptimal plan to move forward that exposes investors to a high degree of clinical risk, requires hundreds of millions of capital and has a low chance of rewarding investors in a manner commensurate with this outsized risk. I will outline a few reasons I rate Forte Biosciences (FBRX) a SELL Institutional Investors Major institutional investors have sold and cut their losses. Forte Biosciences had an enviable roster of professional investors including BVF, Orbimed and Perceptive Advisors. These are seasoned investors with a staff of PhD/MDs who are highly capable of assessing the future likelihood of success. All three funds sold their entire stake in the company. This is not always the case after a clinical failure. There are many cases where institutional investors increase their stake at a low price. Three institutional investors selling their entire stake strongly suggests these professionals do not see a bright future. For an unprofitable biotech company, institutional investors are an important source of capital. Funding an unprofitable biotech in the capital markets is very challenging currently. It is not clear Forte will be able to obtain future funding and if they do, terms will likely be unfavorable. What is clear is they have very limited cash ($38.5 m currently) and they will need hundreds of million to develop the new molecule. In fact, they have a shelf registration in place. Investors should expect substantial dilution. The Plan Forward The asset the company intends to move forward after the failure of FB-401 in atopic dermatitis is FB-102. Given this asset is in the very early stages of testing, prudence dictates an assessment as to whether the risk is worth the potential reward. This molecule may enter the clinic for testing as late as 2024. The company's presentation noted development plans in graft versus host disease (GvHD), vitiligo and alopecia areata which represent combined markets of over $6 billion. Each indication will require separate clinical trials to prove safety and efficacy adding substantially to the cost of development. Each of these indications has standard of care treatments. The company notes an unmet medical need. GvHD is a disease where there is a legitimate unmet need but there are other companies much further along in testing including Seres Therapeutics (MCRB) and MaaT Pharma. The unmet need may be satisfied by these entrants and MaaT has already produced favorable safety and efficacy data. Alopecia and vitiligo have very effective treatments currently-JAK inhibitors. The company noted the safety profile of JAK inhibitors. Opzelura is a topical JAK and most Doctors consider the safety profile of the cream to be of no concern whatsoever. In alopecia, where oral JAKS are approved, the safety and efficacy data for all 3 JAK inhibitors (Pfizer, Lilly and Concert) has been favorable but there is a black box warning. From an efficacy standpoint, there is no unmet need. From a safety standpoint, the mechanism of action and side effect profile are related. The JAK inhibitors work in vitiligo and alopecia areata by suppressing the immune system. There is nothing to suggest FB-102 can achieve the suppression of the immune system required for efficacy without the same safety issues. Investors are going to spend hundreds of million dollars developing treatments in indications where there are either treatments approved or assets years ahead of Forte's molecule, FB-102. Investors are taking on a huge amount of risk to enter crowded markets with little assurance of any competitive advantage. Of course, there is also the possibility the molecule does not show efficacy or adequate safety and needs to abandoned leaving Forte with no assets. To make development of FB-102 worthwhile, it would have to offer a benefit over existing treatments. The company presentation does not include the mechanism of action of FB-102 making it impossible to ascertain whether the "proprietary molecule" that involves "antagonism of a pathway for autoimmune disease" has any advantages or is even likely to work. The company cites infrequent dosing as a potential benefit of the treatment. This is an extraordinarily poor reason to spend hundreds of millions to develop a treatment. Dosing is a very unimportant issue in diseases such as GvHD which can be fatal. Vitiligo and alopecia areata are diseases where patients have skin discolorations or baldness and patients are highly motivated to take their medicine.
Seeking Alpha • Jul 07

Forte Biosciences large shareholders make demands for company's future

A pair of large shareholders of Forte Biosciences (NASDAQ:FBRX) are making demands that could impact the company's future, including the suggestion that the company liquidate. In a Wednesday SEC filing, Brad Leonard, managing member of BML Capital Management, which has a 9.1% stake in common shares, wrote that "Forte shareholders would be best served by a complete liquidation as soon as possible." Forte (FBRX) and some shareholders have been at odds over the future of Forte's only asset, FB-102, which is in the preclinical stage for several indications, including alopecia and vitiligo, a conditions that affects skin pigmentation. Leonard noted that since a May announcement on development plans, there has not been a single insider purchase. On Tuesday, Jacob Ma-Weaver, managing member of Funicular Funds, said in a SEC filing that Forte's board had yet to make an "adequate assessment of the potential immediate value creation that could be achieved through a substantial buyback program, tender offer at a premium, or special dividend." Funicular has a 7.5% stake. Seeking Alpha's Quant Rating views Forte (FBRX) as a hold with the only high grade being for valuation.
Articolo di analisi • Dec 23

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Mar 13

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Articolo di analisi • Jan 19

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

A look at the shareholders of Forte Biosciences, Inc. ( NASDAQ:FBRX ) can tell us which group is most powerful...
Articolo di analisi • Nov 25

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

Rendimenti per gli azionisti

FBRXUS BiotechsUS Mercato
7D0.1%-5.3%-1.0%
1Y589.9%37.0%14.1%

Ritorno vs Industria: FBRX ha superato il US Biotechs che ha restituito 37 % nell'ultimo anno.

Rendimento vs Mercato: FBRX ha superato il mercato US che ha restituito 14.1 % nell'ultimo anno.

Volatilità dei prezzi

Is FBRX's price volatile compared to industry and market?
FBRX volatility
FBRX Average Weekly Movement26.3%
Biotechs Industry Average Movement9.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di FBRX è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale di FBRX è aumentata da 18% a 26% nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
n/a23Paul A. Wagnerwww.fortebiorx.com

Forte Biosciences, Inc. opera negli Stati Uniti come azienda biofarmaceutica in fase clinica. Il principale prodotto candidato dell'azienda è FB-102, un anticorpo monoclonale proprietario anti-CD122 per varie indicazioni autoimmuni e autoimmuni-correlate, come la celiachia, la vitiligine, l'alopecia areata e il diabete di tipo 1. La società ha sede a Dallas, in Texas.

Forte Biosciences, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Forte Biosciences con la sua capitalizzazione di mercato?
FBRX statistiche fondamentali
Capitalizzazione di mercatoUS$1.94b
Utili (TTM)-US$87.94m
Ricavi(TTM)n/a
0.0x
Rapporto P/S
-22.1x
Rapporto P/E

FBRX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
FBRX Conto economico (TTM)
RicaviUS$0
Costo del fatturatoUS$0
Profitto lordoUS$0
Altre speseUS$87.94m
Utili-US$87.94m

Ultimi utili riportati

Jun 30, 2026

Prossima data di guadagno

n/a

Utile per azione (EPS)-3.49
Margine lordo0.00%
Margine di profitto netto0.00%
Rapporto debito/patrimonio netto0%

Come si è comportato FBRX nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/26 15:50
Prezzo dell'azione a fine giornata2026/08/26 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Forte Biosciences, Inc. è coperta da 10 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Etzer DaroutBarclays
Kalpit PatelB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets